7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 
      
    		                         
      cash flows from operating activities
    		                         
      net income
    		-81,566,000 -70,505,000 -70,725,000 -70,024,000 -72,705,000 -55,987,000 -53,344,000 -55,186,000 -39,659,000 -31,083,000 -25,831,000 -23,059,000 -35,542,000 -27,403,000 -26,029,000 -32,424,000 -24,330,000 -28,933,000 -15,090,000 -29,711,000 -21,403,000 -16,207,000 -11,886,000 -15,611,000 -15,554,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                         
      stock-based compensation expense
    		9,261,000 9,055,000 8,784,000 7,176,000 7,468,000 7,656,000 7,398,000 6,116,000 5,739,000 4,798,000 4,844,000 4,040,000 11,731,000 4,161,000 3,311,000 2,642,000 2,612,000 2,436,000 2,364,000 1,916,000 1,546,000 1,323,000 1,237,000 670,000 483,000 
      depreciation
    		   15,000 1,000 1,000 1,000 2,000 5,000 11,000 11,000 10,000 11,000 11,000 11,000 11,000          
      non-cash lease expense
    		69,000 68,000 66,000 65,000 64,000 62,000 62,000 60,000 59,000 58,000 57,000 55,000 55,000 54,000 53,000 52,000       54,000   
      net amortization of premiums and discounts on marketable securities
    		-2,429,000 -2,860,000 -2,463,000                       
      amortization of debt issuance costs and discount
    		179,000 186,000 178,000 174,000 164,000 157,000 112,000 120,000 116,000 112,000 100,000 94,000 94,000             
      loss on extinguishment of loan payable
    		                         
      fair value change in warrant liability
    		-400,000 104,000 102,000 -9,000 39,000 -13,000 500,000 -39,000 8,000 -77,000 187,000 235,000              
      unrealized foreign exchange gain and loss
    		   -86,000 86,000 3,000 -22,000 18,000 -6,000 5,000 -25,000 28,000 12,000 -15,000 -9,000 118,000          
      acquired in-process research and development expense
    		   0 0                     
      changes in operating assets and liabilities:
    		                         
      prepaid expenses and other assets
    		5,489,000 4,660,000 444,000 2,145,000 -13,761,000 -8,071,000 2,337,000 11,053,000 -17,421,000 133,000 -505,000 -545,000 535,000 -608,000 2,730,000 1,128,000 -381,000 -61,000 -2,787,000 3,161,000 4,880,000 -10,143,000 724,000 590,000 -1,794,000 
      accounts payable
    		7,176,000 2,392,000 1,811,000 -16,110,000 10,569,000 1,093,000 6,456,000 -4,229,000 1,339,000 2,876,000 -631,000 1,676,000 -853,000 2,392,000 -2,247,000 -196,000 4,590,000 -2,298,000 1,177,000 -1,208,000 2,100,000 1,001,000 588,000 854,000 -1,597,000 
      accrued expenses and other current liabilities
    		-6,408,000 8,699,000 -5,791,000 12,644,000 1,454,000 157,000 4,344,000 -2,836,000 3,430,000 2,224,000 -1,872,000 -7,793,000 -645,000 1,887,000 -782,000 1,661,000 2,601,000 8,618,000 -4,143,000 2,305,000 -711,000 1,459,000 -1,931,000 1,952,000 5,250,000 
      operating lease liability
    		-73,000 -71,000 -70,000 -68,000 -66,000 -63,000 -62,000 -60,000 -60,000 -75,000 -36,000 -55,000 -52,000 -50,000 -49,000 -48,000          
      net cash (used in) operating activities
    		-67,171,000                         
      cash flows from investing activities
    		                         
      purchase of short-term and long-term marketable securities
    		-73,496,000 -75,676,000 -583,301,000 -79,728,000 -57,933,000 -339,407,000 -38,976,000 -58,214,000 -161,197,000                 
      proceeds from maturities of short-term marketable securities
    		130,277,000 155,016,000 101,118,000 95,000,000 131,000,000 84,510,000 96,825,000 71,000,000 35,500,000 60,500,000 42,500,000 1,000 3,000,000 11,870,000 22,750,000 12,000,000 33,841,000 21,000,000 19,000,000 26,900,000 21,560,000 28,600,000 18,500,000   
      purchase of in-process research and development
    		   0 0                     
      net cash (used in) investing activities
    		56,781,000                         
      cash flows from financing activities
    		                         
      proceeds from the exercise of stock options
    		3,371,000 2,975,000 7,396,000 8,242,000 3,131,000 3,000 1,769,000 450,000 806,000 1,555,000 456,000 2,787,000 2,082,000 0 147,000 114,000 219,000 393,000 24,000 19,000 163,000 9,000 112,000 30,000 0 
      proceeds from the issuance of common stock pursuant to employee stock purchase plan purchases
    		0   140,000 0   83,000 0   102,000 0   158,000          
      proceeds from the issuance of common stock and pre-funded warrants in a follow-on public offering
    		0 0 378,350,000                       
      proceeds from the issuance of common stock in a follow-on public offering
    		   0                      
      proceeds from the issuance of common stock pursuant to the atm offering
    		0 0 10,361,000 67,638,000 0 0 10,604,000 0 0                 
      proceeds from loan payable
    		   0 0 0 10,000,000 0 0 0 15,000,000 0 0             
      repayment of loan payable
    		                         
      payment of debt and equity issuance costs
    		0 0 -576,000 -29,000 -64,000 -477,000 -274,000 -31,000 0                 
      net cash from financing activities
    		-34,027,000 3,433,000 395,531,000 75,991,000 3,067,000 -150,000 366,938,000 502,000 806,000 336,855,000 15,153,000 2,723,000 217,900,000 34,877,000 132,000 243,000 69,000 266,000 24,000 59,000 202,784,000 100,000 164,000 115,000 -1,607,000 
      net increase in cash and cash equivalents
    		-44,417,000 34,527,000 -154,316,000                       
      cash and cash equivalents at the beginning of the period
    		0 0 340,238,000                       
      cash and cash equivalents at the end of the period
    		-44,417,000 34,527,000 185,922,000                       
      supplemental disclosures of cash flow information:
    		                         
      cash paid for interest
    		1,239,000 997,000 980,000 1,034,000 1,087,000 1,093,000 768,000 768,000 766,000 670,000 279,000 252,000              
      non-cash investing and financing information:
    		                         
      change in net unrealizable gain on marketable securities
    		838,000 -97,000 137,000 -1,155,000    776,000 -255,000   37,000 3,000 27,000 -3,000 -10,000 -8,000         
      warrant liability costs reclassified to additional paid-in equity on vested warrants issued
    		   0 0 0 431,000 0 0 0 330,000               
      debt and equity issuance costs included in accounts payable and accrued expenses and other current liabilities
    		   -8,000 -49,000 -416,000 480,000                   
      net cash from operating activities
    		  -67,664,000 -67,090,000 -70,424,000 -57,453,000 -35,140,000 -48,627,000 -49,719,000 -22,389,000 -24,632,000 -25,508,000 -24,624,000 -19,509,000 -22,876,000 -26,695,000 -14,606,000 -20,034,000 -18,346,000 -23,395,000 -13,508,000 -22,584,000 -11,317,000 -11,649,000  
      capex
    		  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
      free cash flows
    		  -67,664,000 -67,090,000 -70,424,000 -57,453,000 -35,140,000 -48,627,000 -49,719,000 -22,389,000 -24,632,000 -25,508,000 -24,624,000 -19,509,000 -22,876,000 -26,695,000 -14,606,000 -20,034,000 -18,346,000 -23,395,000 -13,508,000 -22,584,000 -11,317,000 -11,649,000  
      net (cash used in) provided by investing activities
    		  -482,183,000                       
      write-off of deferred offering costs
    		       0 0 0 337,000               
      net cash from investing activities
    		   15,272,000 73,067,000 -255,896,000 57,849,000 12,786,000 -125,697,000 -128,302,000 17,590,000 -101,445,000 3,000,000 11,870,000 22,750,000 12,000,000 21,934,000 -10,654,000 19,000,000 17,899,000 -59,844,000 38,465,000 -6,281,000   
      proceeds from the issuance of common stock pursuant to registered direct offering
    		       0 0                 
      proceeds from the issuance of common stock pursuant to private offering
    		           0 0             
      net increase in cash, cash equivalents and restricted cash
    		   24,173,000 5,710,000 -313,499,000 389,647,000 -35,339,000 -174,610,000 186,164,000 8,111,000 -124,230,000 196,276,000 27,238,000 6,000 -14,452,000   678,000 -5,437,000 129,432,000   -83,047,000 -14,819,000 
      cash, cash equivalents and restricted cash at the beginning of the period
    		   0 0 0 234,207,000 0 0 0 249,881,000 0 0    0 0 187,390,000  0 0 64,848,000   
      cash, cash equivalents and restricted cash at the end of the period
    		     -313,499,000 623,854,000 -35,339,000 -174,610,000 186,164,000 257,992,000 -124,230,000 196,276,000    7,397,000 -30,422,000 188,068,000  129,432,000 15,981,000 47,414,000   
      deferred offering costs reclassified to additional paid-in equity
    		       0 0   0 0             
      net amortization of premiums and discounts on short-term investments
    		    -3,737,000 -3,447,000 -2,922,000 -3,646,000 -3,269,000 -1,371,000 -1,268,000 -194,000 1,000 46,000 135,000 361,000       -103,000   
      stock options exercises included in other current assets
    		                         
      proceeds from the issuance of common in a follow-on public offering
    		     0 344,839,000                   
      change in net unrealizable loss on marketable securities
    		     -182,000 -349,000                   
      purchase of short-term marketable securities
    		          -24,910,000     0 -11,907,000   -8,996,000 -81,260,000 0 -24,781,000   
      payment of loan payable issuance costs
    		          -25,000 0 -140,000             
      payment of follow-on public offering issuance costs
    		          -278,000               
      payment of deferred offering costs
    		           -40,000 -30,000 -46,000 -15,000 -29,000          
      change in net unrealizable loss on short-term marketable securities
    		          -16,000               
      deferred offering costs included in accounts payable and accrued expenses and other current liabilities
    		          189,000 -8,000 0 0 15,000  -119,000         
      proceeds from the issuance of common stock in a follow-on public offering, net of underwriting costs
    		           0              
      payment of private equity offering costs
    		           0              
      equity issuance costs included in accounts payable and accrued expenses and other current liabilities
    		           -78,000 154,000             
      supplemental disclosures of non-cash investing and financing information:
    		                         
      debt issuance costs included in accounts payable and accrued expenses and other current liabilities
    		                         
      cash, cash equivalents and restricted cash at the beginning of the year
    		              150,591,000           
      cash, cash equivalents and restricted cash at the end of the year
    		              150,597,000           
      other liabilities
    		                         
      proceeds from sales of short-term marketable securities
    		                         
      purchase of property and equipment
    		                         
      proceeds from the issuance of common stock in follow-on public offering, net of issuance costs and underwriting fees
    		                         
      proceeds from the issuance of common stock in initial public offering, net of issuance costs and underwriting fees
    		                         
      proceeds from the disgorgement of stockholders' short-swing profits
    		                      52,000   
      proceeds from the early exercise of stock options in exchange for restricted common stock
    		                       0 21,000 
      ​
    		                         
      right of use asset obtained in exchange for operating lease liability
    		                         
      remeasurement of right of use asset and operating lease liability
    		                         
      conversion of convertible preferred stock into common stock
    		                       0 0 
      rou asset obtained in exchange for operating lease liability
    		                         
      remeasurement of rou asset and lease liability
    		                    0     
      net decrease in cash, cash equivalents and restricted cash
    		                      -17,434,000   
      net unrealizable gain on marketable securities
    		                  1,000 -19,000 -74,000 45,000 51,000   
      proceeds from issuance of common stock in initial public offering, net of issuance costs and underwriting fees
    		                       0 -1,628,000 
      payment of initial public offering costs
    		                         
      shares issued in connection with amgen agreement
    		                         
      acquisition of technology in connection with amgen agreement
    		                         
      issuance date fair-value of anti-dilution liability
    		                         
      change in fair value of preferred stock tranche liability
    		                         
      change in fair value of anti-dilution right liability
    		                         
      proceeds from issuance of series a redeemable convertible preferred stock
    		                         
      proceeds from issuance of series b redeemable convertible preferred stock
    		                         
      payment of preferred stock issuance costs
    		                         
      cash and restricted cash at the beginning of the year
    		                         
      net unrealizable loss on marketable securities
    		                         
      accretion of redeemable convertible preferred stock to redemption value
    		                         
      issuance date fair value of preferred stock tranche obligation
    		                         
      settlement of future purchase obligation
    		                         
      issuance of series a redeemable convertible preferred stock in settlement of anti dilution right liability
    		                         
      extinguishment of call option liability
    		                         
      proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
    		                         
      cash and restricted cash at beginning of period
    		                        0 
      cash, cash equivalents and restricted cash at end of period
    		                        -14,819,000 
      common stock issued in connection with amgen agreement
    		                         
      
    		                         
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.